|
Market Closed -
London S.E.
11:35:12 2026-10-16 am EDT
|
5-day change | 1st Jan Change | ||
| 1,862.50 GBX | -0.32% |
|
+6.43% | +2.08% |
| Oct. 16 | UK stocks set for weekly gains as investors seek shelter in defensive sectors | RE |
| Oct. 15 | Pennsylvania secures $4 billion in investments, governor says | RE |
| Market Cap | 74.63B 99.5B 88.59B 81.96B 140B 9,430B 143B 989B 387B 4,920B 372B 365B 15,703B | P/E 2026 * |
14.2x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 95.79B 128B 114B 105B 180B 12,103B 183B 1,269B 496B 6,314B 478B 469B 20,155B | EV / Sales 2026 * |
2.82x | EV / Sales 2027 * | 2.62x |
| Free-Float |
92.75% | Yield 2026 * |
3.73% | Yield 2027 * | 4.01% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
OTC Markets
| GLAXF | Delayed | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
Deutsche Boerse AG
| GS71 | Delayed |
Last Transcript: GSK plc
| 1 day | -0.32% | ||
| 1 week | +6.43% | ||
| Current month | +1.66% | ||
| 1 month | -1.97% | ||
| 3 months | -2.82% | ||
| 6 months | -13.13% | ||
| Current year | +2.08% |
| 1 week | 1,740 |  | 2,158 |
| 1 month | 1,735.5 | | 2,158 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,592 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/22/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 9/18/26 | Buy | Director | 768 | 0.0000% | ||
| 9/18/26 | Buy | Director | 1,734 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.32% | +6.43% | +14.62% | +23.82% | 99.56B | |
| +0.43% | +6.59% | +56.57% | +106.64% | 1,120B | |
| +0.90% | -2.25% | +32.26% | +63.73% | 616B | |
| +0.71% | +3.24% | +24.33% | +91.33% | 504B | |
| -0.13% | +5.98% | +33.66% | +50.18% | 367B | |
| +0.52% | +0.24% | +72.13% | +40.11% | 360B | |
| -0.95% | +4.70% | +19.65% | +42.71% | 288B | |
| -1.98% | +3.73% | -0.89% | +10.43% | 258B | |
| -0.35% | +4.25% | +44.74% | +52.06% | 234B | |
| -0.75% | +3.32% | +27.18% | +94.07% | 194B | |
| Average | -0.19% | +3.90% | +32.43% | +57.51% | 404.05B | |
| Weighted average by Cap. | +0.12% | +3.90% | +38.73% | +70.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.91B 45.21B 40.26B 37.24B 63.83B 4,285B 64.89B 449B 176B 2,235B 169B 166B 7,136B | 35.52B 47.36B 42.17B 39.01B 66.86B 4,488B 67.97B 471B 184B 2,341B 177B 174B 7,474B |
| Net income | 5.32B 7.1B 6.32B 5.84B 10.02B 672B 10.18B 70.51B 27.57B 351B 26.56B 26.04B 1,120B | 6.31B 8.41B 7.49B 6.93B 11.87B 797B 12.07B 83.57B 32.68B 416B 31.48B 30.87B 1,327B |
| Net Debt | 21.16B 28.21B 25.12B 23.23B 39.82B 2,673B 40.48B 280B 110B 1,395B 106B 104B 4,452B | 18.27B 24.36B 21.69B 20.06B 34.39B 2,309B 34.96B 242B 94.64B 1,204B 91.17B 89.4B 3,844B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-16 | GBX 1,862.50 | -0.32% | 12,806,915 |
| 26-10-15 | GBX 1,868.50 | +2.89% | 12,523,823 |
| 26-10-14 | GBX 1,816.00 | +3.59% | 7,627,221 |
| 26-10-13 | GBX 1,753.00 | -1.02% | 6,613,488 |
| 26-10-12 | GBX 1,771.00 | +1.20% | 3,352,492 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
